Skip to content
drillr.ai

VANI

Vivani Medical, Inc.

NASDAQ · USHealthcareMedical - Devices
$1.35+2.27%

Price as of Jul 20, 2026

VANI news

Vivani Medical, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

    ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or twice-yearly administration, today announced that it will present at the Emerging Growth Conference on July 15, 2026. Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference.

    Globe Newswire ·

  2. Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

    Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company’s semaglutide drug implant. NPM-139, which utilizes Vivani’s Nano

    Globe Newswire ·

  3. Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

    ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of August Moretti to its board of directors. Concurrent with this appointment, the Company announced the retirement of Dr. Dean Baker from the board. “We are pleased to welcome August Moretti to our board at this transformative stage for Vivani,” said G

    Globe Newswire ·

  4. Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

    ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (https://www.globenewswire.com/Tracker?data=j7FyVFemzFmeL2wfx4DK7aHnZnbfDrYXlZrwB4fyUudP8l6CMYRTVtfPJJ52rCguA8EJnM8FtEB_iJhFXpRb89o717-kvrNciqWy39yp5Hxn5ejSX1rnKqpLasqTGxh2MqX187jl2gYAObBJo6VH-s415H-n3IaezArYaSY0kALg8tJ0r3dXvfSLcWebYLU_7wmkXPXZ2pv-PoagvWHG9yfip8GOHFRapYldKmzaEDXAnhOKzMzqkzdxf2Qn_IX4VryLCCVKTxeK5wKn9J9zZgu9sxz4WccuGl-zTP5kw3N_Vw4wWbB2sWTzUVdLY8zqv3NFedO6Vcx1OBc08LaiKkAL-z3ZhhB9uU9G7IcWiI2V_sLz3hWJtBUV7t2SreR2

    Globe Newswire ·

  5. Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026. Single preclinical administration of semaglutide implant configuration demonstrates continued semaglutide exposure and >20% sham-adjusted weight loss for a full year. Solid cash po

    Globe Newswire ·